BG
IBRX icon

BlackRock Group’s ImmunityBio IBRX Stock Holding History

BlackRock Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$18K Hold
3,100
– – ﹤0.01% 2960
2016
Q3 		$24K Hold
3,100
– – ﹤0.01% 2968
2016
Q2 		$19K Hold
3,100
– – ﹤0.01% 2995
2016
Q1 		$25K Buy
+3,100
New +$29.2K ﹤0.01% 3014
2015
Q4 		– Sell
-41,846
Closed -$480K – 3026
2015
Q3 		$480K Buy
+41,846
New +$913K ﹤0.01% 2216

Other funds holding IBRX

WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Group's IBRX Position: Q4 2016 in Review

BlackRock Group held its ImmunityBio (IBRX) position steady in Q4 2016 at 3,100 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #2960.

BlackRock Group first reported a position in IBRX in Q3 2015 and has held it in 5 quarters since. The position peaked at $480K in Q3 2015. 68 funds tracked by Wall St. Rank hold IBRX as of Q4 2016.

  • BlackRock Group held 3,100 shares of ImmunityBio worth $18K as of Q4 2016.
  • BlackRock Group left its ImmunityBio share count unchanged in Q4 2016.
  • ImmunityBio made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2960 holding.
  • BlackRock Group first reported a position in ImmunityBio in Q3 2015 and has held it in 5 quarters since.
  • BlackRock Group's ImmunityBio position peaked at $480K in Q3 2015.
  • 68 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.